Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $166.0 million.

  • Adma Biologics' Non-Current Assets rose 12924.68% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $640.9 million, marking a year-over-year increase of 11965.88%. This contributed to the annual value of $157.3 million for FY2024, which is 11791.63% up from last year.
  • Latest data reveals that Adma Biologics reported Non-Current Assets of $166.0 million as of Q3 2025, which was up 12924.68% from $158.8 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Non-Current Assets ranged from a high of $166.0 million in Q3 2025 and a low of $58.4 million during Q1 2021
  • In the last 5 years, Adma Biologics' Non-Current Assets had a median value of $74.5 million in 2024 and averaged $90.0 million.
  • In the last 5 years, Adma Biologics' Non-Current Assets crashed by 754.56% in 2023 and then soared by 12924.68% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Non-Current Assets stood at $67.5 million in 2021, then rose by 15.6% to $78.1 million in 2022, then dropped by 7.55% to $72.2 million in 2023, then surged by 117.92% to $157.3 million in 2024, then increased by 5.57% to $166.0 million in 2025.
  • Its last three reported values are $166.0 million in Q3 2025, $158.8 million for Q2 2025, and $158.8 million during Q1 2025.